INT3894

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.52
First Reported 1977
Last Reported 2007
Negated 0
Speculated 0
Reported most in Abstract
Documents 18
Total Number 18
Disease Relevance 2.70
Pain Relevance 5.77

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (Gcg) extracellular region (Gcg) cytoplasm (Gcg)
Anatomy Link Frequency
plasma 2
pancreas 2
Gcg (Rattus norvegicus)
Pain Link Frequency Relevance Heat
Somatostatin 37 100.00 Very High Very High Very High
Clonidine 10 100.00 Very High Very High Very High
conotoxin 9 99.98 Very High Very High Very High
tetrodotoxin 7 99.98 Very High Very High Very High
antagonist 10 99.76 Very High Very High Very High
substance P 7 99.74 Very High Very High Very High
narcan 9 99.48 Very High Very High Very High
aspirin 6 98.08 Very High Very High Very High
tolerance 6 95.32 Very High Very High Very High
agonist 2 94.44 High High
Disease Link Frequency Relevance Heat
Hypoglycemia 8 100.00 Very High Very High Very High
Acquired Immune Deficiency Syndrome Or Hiv Infection 1 99.58 Very High Very High Very High
Diabetes Mellitus 13 99.46 Very High Very High Very High
Hyperinsulinism 1 99.36 Very High Very High Very High
Iron Overload 3 97.88 Very High Very High Very High
Impaired Glucose Tolerance 3 95.32 Very High Very High Very High
Pancreatitis 2 90.88 High High
Injury 1 89.68 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Also, both 100 mumol/l acetylsalicylic acid (cyclooxygenase inhibitor) and 100 mumol/l caffeic acid (lipoxygenase inhibitor) significantly inhibited clonidine-induced glucagon secretion (P less than 0.01, respectively), whereas neither 10 mumol/l acetylsalicylic acid nor 10 mumol/l caffeic acid affected clonidine-induced glucagon secretion.
Negative_regulation (inhibited) of Localization (secretion) of glucagon associated with aspirin and clonidine
1) Confidence 0.52 Published 1992 Journal Diabetes Res. Clin. Pract. Section Abstract Doc Link 1330464 Disease Relevance 0 Pain Relevance 0.60
The phospholipase A2 inhibitor mepacrine at 25 and 50 mumol/l significantly inhibited glucagon secretion induced by 0.1 mumol/l clonidine (P less than 0.01, respectively), whereas 5 mumol/l mepacrine did not affect clonidine-induced glucagon secretion.
Negative_regulation (inhibited) of Localization (secretion) of glucagon associated with clonidine
2) Confidence 0.52 Published 1992 Journal Diabetes Res. Clin. Pract. Section Abstract Doc Link 1330464 Disease Relevance 0 Pain Relevance 0.55
The enhanced glucagon response to arginine and the nonsuppressibility of glucagon secretion by oral glucose found in these patients were similar to the results found in the same tests performed in our previous series of patients with "idiopathic" diabetes and at variance with those reported by others in patients with chronic pancreatitis.
Negative_regulation (nonsuppressibility) of Localization (secretion) of glucagon associated with diabetes mellitus and chronic pancreatitis
3) Confidence 0.42 Published 1977 Journal Diabetologia Section Abstract Doc Link 908475 Disease Relevance 0.79 Pain Relevance 0.09
Elevation of glucose from 1.6 to 8.3 mmol/l increased insulin and somatostatin secretion and inhibited glucagon release.
Negative_regulation (inhibited) of Localization (release) of glucagon associated with somatostatin and hyperinsulinism
4) Confidence 0.42 Published 1992 Journal Diabetologia Section Abstract Doc Link 1478364 Disease Relevance 0.10 Pain Relevance 0.44
Doses of 2 and 10 micrograms/kg of this analog completely suppressed the hypoglycemia-induced glucagon release.
Negative_regulation (suppressed) of Localization (release) of glucagon associated with hypoglycemia
5) Confidence 0.34 Published 1987 Journal Life Sci. Section Abstract Doc Link 2886886 Disease Relevance 0.19 Pain Relevance 0.24
RC-160 suppressed the secretion of glucagon, the inhibition being dose-dependent in the range of 0.1 to 2 micrograms/kg.
Negative_regulation (suppressed) of Localization (secretion) of glucagon
6) Confidence 0.34 Published 1987 Journal Life Sci. Section Abstract Doc Link 2886886 Disease Relevance 0.19 Pain Relevance 0.32
The N-type Ca2+-channel blocker omega-conotoxin and the Na+-channel blocker tetrodotoxin inhibited glucose-induced glucagon release whereas tetraethylammonium, a blocker of delayed rectifying K+ channels, increased secretion.
Negative_regulation (inhibited) of Localization (release) of glucagon associated with tetrodotoxin and conotoxin
7) Confidence 0.33 Published 2005 Journal Endocrinology Section Abstract Doc Link 16081632 Disease Relevance 0 Pain Relevance 0.23
This correlated with a doubling of glucagon secretion by glucose in intact rat islets exposed to diazoxide and high K+.
Negative_regulation (doubling) of Localization (secretion) of glucagon
8) Confidence 0.33 Published 2005 Journal Endocrinology Section Abstract Doc Link 16081632 Disease Relevance 0 Pain Relevance 0.21
Glucagon release increased monotonically with increasing K+ concentrations. omega-Conotoxin suppressed glucagon release to 15 mM K+, whereas a combination of omega-conotoxin and an L-type Ca2+-channel inhibitor was required to abrogate secretion in 50 mM K+.
Negative_regulation (suppressed) of Localization (release) of glucagon associated with conotoxin
9) Confidence 0.33 Published 2005 Journal Endocrinology Section Abstract Doc Link 16081632 Disease Relevance 0 Pain Relevance 0.23
Atropine, yohimbine but not naloxone significantly (p < 0.05) inhibited Leu-Enk-evoked glucagon release from normal rat pancreas.
Negative_regulation (inhibited) of Localization (release) of glucagon in pancreas associated with narcan
10) Confidence 0.33 Published 2001 Journal Arch. Physiol. Biochem. Section Abstract Doc Link 11880925 Disease Relevance 0.30 Pain Relevance 0.30
Based on prior reports that sst2 tonically suppresses glucagon secretion, the antagonist most likely increased glucagon secretion from the pancreatic alpha-cells, with resultant increases in plasma glucose and then insulin.
Negative_regulation (suppresses) of Localization (secretion) of glucagon in plasma associated with antagonist
11) Confidence 0.31 Published 2002 Journal Endocrinology Section Abstract Doc Link 11897676 Disease Relevance 0 Pain Relevance 0.72
Pramlintide, an adjunct treatment to mealtime insulin for patients with type 2 and type 1 diabetes, aids glycemic control by suppressing postprandial glucagon secretion, slowing gastric emptying, and enhancing satiety.
Negative_regulation (suppressing) of Localization (secretion) of glucagon associated with diabetes mellitus and acquired immune deficiency syndrome or hiv infection
12) Confidence 0.28 Published 2007 Journal J Clin Pharmacol Section Abstract Doc Link 17463219 Disease Relevance 0.35 Pain Relevance 0.29
These results indicate that analogs RC-160 and RC-121 possess prolonged and enhanced biological activities, the former analog showing a high selectivity in inhibiting GH and glucagon release in vivo as compared with that of insulin secretion.
Negative_regulation (inhibiting) of Localization (release) of glucagon
13) Confidence 0.25 Published 1987 Journal Life Sci. Section Abstract Doc Link 2886886 Disease Relevance 0.18 Pain Relevance 0.14
Since previous studies have shown that insulin, the major regulatory hormone of glucose metabolism, reduces gastric somatostatin and glucagon secretion it was of interest to determine the effect of insulin on gastric BLI and gastrin secretion.
Negative_regulation (reduces) of Localization (secretion) of glucagon associated with somatostatin
14) Confidence 0.21 Published 1986 Journal Neuropeptides Section Abstract Doc Link 3513044 Disease Relevance 0 Pain Relevance 0.27
Pancreatic release of glucagon to insulin-induced hypoglycaemia was diminished, but suppressive response of the hormone to glucose-induced hyperglycaemia was well preserved.
Negative_regulation (diminished) of Localization (release) of glucagon associated with hypoglycemia
15) Confidence 0.12 Published 1983 Journal Diabetologia Section Abstract Doc Link 6363179 Disease Relevance 0.45 Pain Relevance 0.17
The effect of substance P on insulin, glucagon, and exocrine secretion was blocked by the NK-1 receptor antagonist.
Negative_regulation (blocked) of Localization (secretion) of glucagon associated with antagonist and substance p
16) Confidence 0.02 Published 2000 Journal Pancreas Section Abstract Doc Link 10766449 Disease Relevance 0 Pain Relevance 0.66
After surgery, glucagon secretory capacity, the integrated incremental secretion of immunoreactive glucagon (sigma delta IRG) during the ITT, decreased significantly in the L-Px, St-Px, and T-Px groups but not in the R-Px group.
Negative_regulation (decreased) of Localization (secretion) of glucagon
17) Confidence 0.02 Published 1989 Journal Diabetes Section Abstract Doc Link 2661285 Disease Relevance 0.08 Pain Relevance 0.16
After surgery, glucagon secretory capacity, the integrated incremental secretion of immunoreactive glucagon (sigma delta IRG) during the ITT, decreased significantly in the L-Px, St-Px, and T-Px groups but not in the R-Px group.
Negative_regulation (decreased) of Localization (secretion) of glucagon
18) Confidence 0.01 Published 1989 Journal Diabetes Section Abstract Doc Link 2661285 Disease Relevance 0.07 Pain Relevance 0.15

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox